Citations (32)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (10)
Ekaterina Pivovarova, Hye Sung Min & Peter D. Friedmann. (2021) Impact of extended release naltrexone on health-related quality of life in individuals with legal involvement and opioid use disorders. Substance Abuse 42:4, pages 618-624.
Read now
Read now
Brendan Saloner, Barbara Andraka Christou, Adam J. Gordon & Bradley D. Stein. (2021) It will end in tiers: A strategy to include “dabblers” in the buprenorphine workforce after the X-waiver. Substance Abuse 42:2, pages 153-157.
Read now
Read now
Gerald Cochran, Julie Bruneau, Nicholas Cox & Adam J. Gordon. (2020) Medication treatment for opioid use disorder and community pharmacy: Expanding care during a national epidemic and global pandemic. Substance Abuse 41:3, pages 269-274.
Read now
Read now
Adam J. Gordon, Karen Drexler, Eric J. Hawkins, Jennifer Burden, Nodira K. Codell, Amy Mhatre-Owens, Matthew T. Dungan & Hildi Hagedorn. (2020) Stepped Care for Opioid Use Disorder Train the Trainer (SCOUTT) initiative: Expanding access to medication treatment for opioid use disorder within Veterans Health Administration facilities. Substance Abuse 41:3, pages 275-282.
Read now
Read now
John M. Majer, Leonard A. Jason, Patrick Hickey, Norris Joshua, Hayoung Jeong & Ted J. Bobak. (2020) Social Support among Oxford House Residents Utilizing Medication-Assisted Treatments. Alcoholism Treatment Quarterly 38:2, pages 199-214.
Read now
Read now
Siv-Elin Leirvaag Carlsen, Linn-Heidi Lunde & Torbjørn Torsheim. (2019) Predictors of quality of life of patients in opioid maintenance treatment in the first year in treatment. Cogent Psychology 6:1.
Read now
Read now
Selahattin Bolek, Ilhan Yargic & Okan Ekinci. (2016) The effects of Buprenorphine/Naloxane Maintenance Treatment on the Quality of Life, Substance Use and Functionality in Opiate Dependence: A Follow-Up Study. Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology 26:2, pages 141-151.
Read now
Read now
Philippe Binder, Nassir Messaadi, Marie-Christine Perault-Pochat, Stéphanie Gagey, Yann Brabant & Pierre Ingrand. (2016) Preference for brand-name buprenorphine is related to severity of addiction among outpatients in opioid maintenance treatment. Journal of Addictive Diseases 35:2, pages 101-108.
Read now
Read now
AngelaM. Wisniewski, MichaelR. Dlugosz & RichardD. Blondell. (2013) Reimbursement and Practice Policies Among Providers of Buprenorphine-Naloxone Treatment. Substance Abuse 34:2, pages 105-107.
Read now
Read now
A. Karow, U. Verthein, R. Pukrop, J. Reimer, C. Haasen, M. Krausz & I. Schäfer. (2011) Quality of Life Profiles and Changes in the Course of Maintenance Treatment Among 1,015 Patients With Severe Opioid Dependence. Substance Use & Misuse 46:6, pages 705-715.
Read now
Read now
Articles from other publishers (22)
Carla C. Garcia, Mark Bounthavong, Adam J. Gordon, Allison M. Gustavson, Marie E. Kenny, Wendy Miller, Aryan Esmaeili, Princess E. Ackland, Barbara A. Clothier, Ann Bangerter, Siamak Noorbaloochi, Alex H. S. Harris & Hildi J. Hagedorn. (2023) Costs of implementing a multi-site facilitation intervention to increase access to medication treatment for opioid use disorder. Implementation Science Communications 4:1.
Crossref
Crossref
Adam J. Gordon, Andrew J. Saxon, Stefan Kertesz, Jessica J. Wyse, Ajay Manhapra, Lewei A. Lin, Wei Chen, Jared Hansen, Derek Pinnell, Tina Huynh, Jacob D. Baylis, Francesca E. Cunningham, Udi E. Ghitza, Gavin Bart, Hong Yu & Brian C. Sauer. (2023) Buprenorphine use and courses of care for opioid use disorder treatment within the Veterans Health Administration. Drug and Alcohol Dependence 248, pages 109902.
Crossref
Crossref
Louisa Degenhardt, Brodie Clark, Georgina Macpherson, Oscar Leppan, Suzanne Nielsen, Emma Zahra, Briony Larance, Jo Kimber, Daniel Martino-Burke, Matthew Hickman & Michael Farrell. (2023) Buprenorphine versus methadone for the treatment of opioid dependence: a systematic review and meta-analysis of randomised and observational studies. The Lancet Psychiatry 10:6, pages 386-402.
Crossref
Crossref
Bradley D. Stein, Brendan K. Saloner, Olivia K. Golan, Barbara Andraka-Christou, Christina M. Andrews, Andrew W. Dick, Corey S. Davis, Flora Sheng & Adam J. Gordon. (2023) Association of Selected State Policies and Requirements for Buprenorphine Treatment With Per Capita Months of Treatment. JAMA Health Forum 4:5, pages e231102.
Crossref
Crossref
Kara Zivin, Lindsay Allen, Andrew J. Barnes, Stefanie Junker, Joo Yeon Kim, Lu Tang, Susan Kennedy, Katherine A. Ahrens, Marguerite Burns, Sarah Clark, Evan Cole, Dushka Crane, David Idala, Paul Lanier, Shamis Mohamoud, Marian Jarlenski, Mary Joan McDuffie, Jeffery Talbert, Adam J. Gordon & Julie M. Donohue. (2022) Design, Implementation, and Evolution of the Medicaid Outcomes Distributed Research Network (MODRN). Medical Care 60:9, pages 680-690.
Crossref
Crossref
Jamey J. Lister, Jennifer D. Ellis, Cara A. Struble, David M. Ledgerwood & Mark K. Greenwald. (2022) Protective Factor Predictors of Abstinence and Retention in Patients Receiving Methadone Treatment for Opioid Use Disorder. International Journal of Mental Health and Addiction.
Crossref
Crossref
Olivia K. Golan, Rachel Totaram, Elizabeth Perry, Kennicia Fortson, Raul Rivera-Atilano, Rebecca Entress, Matthew Golan, Barbara Andraka-Christou, Daniel Whitaker & Therese Pigott. (2022) Systematic review and meta-analysis of changes in quality of life following initiation of buprenorphine for opioid use disorder. Drug and Alcohol Dependence 235, pages 109445.
Crossref
Crossref
Stijn Veldman, Maria van Beek, Steffie van Rijswijk, Hannah Ellerbroek, Hans Timmerman, Selina van der Wal, Monique Steegers & Arnt Schellekens. (2022) Effects of opioid rotation to buprenorphine/naloxone on pain, pain thresholds, pain tolerance, and quality of life in patients with chronic pain and opioid use disorder. Pain 163:5, pages 955-963.
Crossref
Crossref
Bradley D. Stein, Brendan Saloner, Rose Kerber, Mark Sorbero & Adam J. Gordon. (2022) Subsequent Buprenorphine Treatment Following Emergency Physician Buprenorphine Prescription Fills: A National Assessment 2019 to 2020. Annals of Emergency Medicine 79:5, pages 441-450.
Crossref
Crossref
Adam J. Gordon, Marie Kenny, Matthew Dungan, Allison M. Gustavson, A. Taylor Kelley, Audrey L. Jones, Eric Hawkins, Joseph W. Frank, Anissa Danner, Joseph Liberto & Hildi Hagedorn. (2022) Are x‐waiver trainings enough? Facilitators and barriers to buprenorphine prescribing after x‐waiver trainings. The American Journal on Addictions 31:2, pages 152-158.
Crossref
Crossref
Hagit Bonny-Noach. (2019) Harm reduction drug policy in Israel: what has been accomplished and what still needs to be done?. Israel Journal of Health Policy Research 8:1.
Crossref
Crossref
Michael D. Stein, Micah T. Conti, Debra S. Herman, Bradley J. Anderson, Genie L. Bailey, Donnell Van Noppen & Ana M. Abrantes. (2019) Worries About Discontinuing Buprenorphine Treatment: Scale Development and Clinical Correlates. The American Journal on Addictions 28:4, pages 270-276.
Crossref
Crossref
Adam J. Gordon, Gerald Cochran, Marcela C. Smid, Ajay Manhapra & Stefan G. Kertesz. 2019. Treating Opioid Addiction. Treating Opioid Addiction
223
238
.
Martin Bråbäck, Louise Brådvik, Katja Troberg, Pernilla Isendahl, Suzan Nilsson & Anders Håkansson. (2018) Health Related Quality of Life in Individuals Transferred from a Needle Exchange Program and Starting Opioid Agonist Treatment. Journal of Addiction 2018, pages 1-7.
Crossref
Crossref
Paul Vanderkam, Stéphanie Gagey, Pierre Ingrand, Marie-Christine Perault-Pochat, Yann Brabant, Clara Blanchard, Benoit Tudrej, Nassir Messaadi & Philippe Binder. (2018) Are patients’ pejorative representations of buprenorphine associated with their level of addiction and of misuse?. Drug and Alcohol Dependence 188, pages 10-15.
Crossref
Crossref
Jeremy W. Bray, Brandon Aden, Ashley A. Eggman, Leah Hellerstein, Eve Wittenberg, Bohdan Nosyk, Judy C. Stribling & Bruce R. Schackman. (2017) Quality of life as an outcome of opioid use disorder treatment: A systematic review. Journal of Substance Abuse Treatment 76, pages 88-93.
Crossref
Crossref
Ralph Lydic, John C. Keifer, Helen A. Baghdoyan, Robert Craft & Chelsea Angel. 2017. Principles and Practice of Sleep Medicine. Principles and Practice of Sleep Medicine
250
259.e6
.
Amanda L. Giordano, Elizabeth A. Prosek, Sahar Loseu, Cynthia M. Bevly, Julia Stamman, Citlali E. Molina, Molly M. Callahan & Richard-Michael Calzada. (2016) Self-Efficacy Among Adults in Substance Abuse Treatment: The Role of Religious Coping. Journal of Addictions & Offender Counseling 37:1, pages 35-48.
Crossref
Crossref
Victoria Manning, Brenda Gomez, Song Guo, Yee Deng Low, Puay Kee Koh & Kim Eng Wong. (2011) An Exploration of Quality of Life and its Predictors in Patients with Addictive Disorders: Gambling, Alcohol and Drugs. International Journal of Mental Health and Addiction 10:4, pages 551-562.
Crossref
Crossref
Hans Tönies. (2012) Biographical data of patients in drug substitution programmesAnalyse von biographischen Daten von substituierten Drogenpatienten. Wiener Medizinische Wochenschrift 162:1-2, pages 39-43.
Crossref
Crossref
P Todd Korthuis, Mary Jo Tozzi, Vijay Nandi, David A Fiellin, Linda Weiss, James E Egan, Michael Botsko, Angela Acosta, Marc N Gourevitch, David Hersh, Jeffrey Hsu, Joshua Boverman & Frederick L Altice. (2011) Improved Quality of Life for Opioid-Dependent Patients Receiving Buprenorphine Treatment in HIV Clinics. JAIDS Journal of Acquired Immune Deficiency Syndromes 56:Supplement 1, pages S39-S45.
Crossref
Crossref
Alexander M. Ponizovsky, Eli Marom, Alexander Zeldin & Nathan I. Cherny. (2010) Trends in opioid analgesics consumption, Israel, 2000–2008. European Journal of Clinical Pharmacology 67:2, pages 165-168.
Crossref
Crossref